• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment.

作者信息

Napolitano M, Caiazzo G, Fabbrocini G, Balato A, Di Caprio R, Scala E, Scalvenzi M, Patruno C

机构信息

Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.

Departments of, Department of, Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

出版信息

Br J Dermatol. 2021 Feb;184(2):341-343. doi: 10.1111/bjd.19459. Epub 2020 Sep 15.

DOI:10.1111/bjd.19459
PMID:33533476
Abstract
摘要

相似文献

1
Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment.在度普利尤单抗治疗期间，具有银屑病样反应的特应性皮炎患者皮损中白细胞介素-23A表达增加。
Br J Dermatol. 2021 Feb;184(2):341-343. doi: 10.1111/bjd.19459. Epub 2020 Sep 15.
2
Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.儿童中重度特应性皮炎患者接受度普利尤单抗治疗后出现银屑病样皮炎。
Pediatr Dermatol. 2021 Nov;38(6):1500-1505. doi: 10.1111/pde.14820. Epub 2021 Oct 14.
3
Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.使用度普利尤单抗治疗的重度特应性皮炎患者的体重增加：一项队列研究。
BMC Dermatol. 2020 Sep 22;20(1):8. doi: 10.1186/s12895-020-00103-0.
4
Dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis.特应性皮炎患者中与度普利尤单抗相关的银屑病和银屑病样皮炎。
Australas J Dermatol. 2022 Aug;63(3):394-397. doi: 10.1111/ajd.13846. Epub 2022 Apr 23.
5
Angioedema: A potential complication of dupilumab in atopic dermatitis.血管性水肿：度普利尤单抗治疗特应性皮炎时的一种潜在并发症。
Pediatr Dermatol. 2021 Jan;38(1):237-238. doi: 10.1111/pde.14434. Epub 2020 Oct 25.
6
Polyenthesitis during treatment with dupilumab for atopic dermatitis.度普利尤单抗治疗特应性皮炎期间的多肌炎。
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e319-e321. doi: 10.1111/jdv.16239. Epub 2020 Feb 19.
7
Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients.两例儿科心脏移植患者应用度普利尤单抗后出现银屑病样皮炎。
Pediatr Dermatol. 2024 May-Jun;41(3):508-511. doi: 10.1111/pde.15497. Epub 2023 Dec 14.
8
Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?特应性皮炎患者使用度普利尤单抗治疗期间的眼表疾病，能否预防？
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e255-e256. doi: 10.1111/jdv.16234. Epub 2020 Feb 13.
9
Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review.度普利尤单抗相关银屑病和银屑病样表现：范围综述。
Dermatology. 2023;239(4):646-657. doi: 10.1159/000530608. Epub 2023 Apr 26.
10
Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?2017 年批准用于治疗特应性皮炎后dupilumab 的新进展：有哪些新进展和下一步计划？
Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):341-349. doi: 10.1097/ACI.0000000000000551.

引用本文的文献

1
Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab.使用度普利尤单抗治疗的特应性皮炎患者的银屑病风险
JAMA Dermatol. 2025 Jun 18. doi: 10.1001/jamadermatol.2025.1578.
2
Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis.超越二分法：理解特应性皮炎和银屑病之间的重叠
Front Immunol. 2025 Feb 10;16:1541776. doi: 10.3389/fimmu.2025.1541776. eCollection 2025.
3
Deciphering the role of IL17RA in psoriasis and chronic mucocutaneous candidiasis: shared pathways and distinct manifestations.
解读白细胞介素17A受体（IL17RA）在银屑病和慢性黏膜皮肤念珠菌病中的作用：共同途径与不同表现
Front Immunol. 2025 Jan 20;15:1516408. doi: 10.3389/fimmu.2024.1516408. eCollection 2024.
4
Research trends and hotspots in biologics for plaque psoriasis: A bibliometric study from 2004 to 2023.斑块状银屑病生物制剂的研究趋势与热点：一项2004年至2023年的文献计量学研究
Heliyon. 2024 Jul 30;10(15):e35446. doi: 10.1016/j.heliyon.2024.e35446. eCollection 2024 Aug 15.
5
Janus Kinase Inhibitors as Successful Treatment Alternative in Dupilumab-Induced Psoriasis.Janus激酶抑制剂作为度普利尤单抗诱导的银屑病的成功治疗替代方案
Case Rep Dermatol. 2024 Jun 17;16(1):144-148. doi: 10.1159/000539124. eCollection 2024 Jan-Dec.
6
Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective.合并症和特殊人群的中重度特应性皮炎患者的生物制剂和小分子治疗：意大利视角
Dermatol Reports. 2023 Sep 13;16(2):9839. doi: 10.4081/dr.2023.9839. eCollection 2024 Jun 14.
7
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors.成人特应性皮炎的靶向全身治疗：从生物制剂和JAK抑制剂中进行选择。
Am J Clin Dermatol. 2024 Mar;25(2):179-193. doi: 10.1007/s40257-023-00837-w. Epub 2024 Jan 12.
8
Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis.生物制剂诱导的银屑病和特应性皮炎患者免疫表型交叉转换
Indian J Dermatol. 2023 Mar-Apr;68(2):186-191. doi: 10.4103/ijd.ijd_871_22.
9
Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review.度普利尤单抗相关银屑病和银屑病样表现：范围综述。
Dermatology. 2023;239(4):646-657. doi: 10.1159/000530608. Epub 2023 Apr 26.
10
Knowledge Mapping and Research Hotspots of Comorbidities in Psoriasis: A Bibliometric Analysis from 2004 to 2022.银屑病共病的知识图谱和研究热点：2004 年至 2022 年的文献计量分析。
Medicina (Kaunas). 2023 Feb 17;59(2):393. doi: 10.3390/medicina59020393.